Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine (Baylor), Houston, TX, USA.
Division of General Internal Medicine, Baylor, Houston, TX, USA.
J Gen Intern Med. 2022 Sep;37(12):3062-3069. doi: 10.1007/s11606-021-07363-7. Epub 2022 Feb 7.
We previously found that a 6-month multidimensional diabetes program, TIME (Telehealth-Supported, Integrated Community Health Workers, Medication-Access) resulted in improved clinical outcomes.
To follow TIME participant clinical outcomes for 24 months PARTICIPANTS: Low-income Latino(a)s with type 2 diabetes DESIGN AND INTERVENTION: We collected post-intervention clinical data for five cohorts (n = 101, mean n = 20/cohort) who participated in TIME programs from 2018 to 2020 in Houston, Texas.
We gathered HbA1c (primary outcome), weight, body mass index (BMI), and blood pressure data at baseline, 6 months (intervention end), and semiannually thereafter until 24 months after baseline to assess sustainability. We also evaluated participant loss to follow-up until 24 months.
Participants decreased HbA1c levels during the intervention (p < 0.0001) and maintained these improvements at each timepoint from baseline to 24 months (p range: < 0.0001 to 0.015). Participants reduced blood pressure levels during TIME and maintained these changes at each timepoint from baseline until 18 months (systolic p range < 0.0001 to 0.0005, diastolic p range: < 0.0001 to 0.008) but not at 24 months (systolic: p = 0.065; diastolic: p = 0.85). There were no significant weight changes during TIME or post-intervention: weight (p range = 0.07 to 0.77), BMI (p range = 0.11 to 0.71). Attrition rates (loss to follow-up during the post-intervention period) were 5.9% (6 months), 24.8% (12 months), 35.6% (18 months), and 41.8% (24 months).
It is possible for vulnerable populations to maintain long-term glycemic and blood pressure improvements using a multiple dimensional intervention. Attrition rates rose over time but show promise given the majority of post-intervention timepoints occurred during the COVID-19 pandemic when low-income populations were most susceptible to suboptimal healthcare access. Future studies are needed to evaluate longitudinal outcomes of diabetes interventions conducted by local clinics rather than research teams.
我们之前发现,为期 6 个月的多维糖尿病项目 TIME(远程医疗支持、综合社区健康工作者、药物获取)可改善临床结果。
随访 TIME 参与者的 24 个月临床结果。
患有 2 型糖尿病的低收入拉丁裔
我们收集了 2018 年至 2020 年在德克萨斯州休斯顿参加 TIME 项目的五组(n = 101,平均 n = 20/组)的干预后临床数据。
我们在基线、6 个月(干预结束时)和此后每半年收集一次 HbA1c(主要结局)、体重、体重指数(BMI)和血压数据,以评估可持续性。我们还评估了参与者在 24 个月的随访期间的失访情况。
参与者在干预期间降低了 HbA1c 水平(p < 0.0001),并在从基线到 24 个月的每个时间点都保持了这些改善(p 范围:< 0.0001 至 0.015)。参与者在 TIME 期间降低了血压水平,并在从基线到 18 个月的每个时间点都保持了这些变化(收缩压 p 范围 < 0.0001 至 0.0005,舒张压 p 范围:< 0.0001 至 0.008),但在 24 个月时没有(收缩压:p = 0.065;舒张压:p = 0.85)。在 TIME 期间或干预后没有体重明显变化:体重(p 范围 = 0.07 至 0.77),BMI(p 范围 = 0.11 至 0.71)。失访率(干预后随访期间失访)为 5.9%(6 个月)、24.8%(12 个月)、35.6%(18 个月)和 41.8%(24 个月)。
使用多维干预措施,弱势群体有可能长期保持血糖和血压改善。随着时间的推移,失访率有所上升,但考虑到大多数干预后时间点发生在 COVID-19 大流行期间,当时低收入人群最容易无法获得最佳医疗保健,这一结果仍有希望。需要进一步研究评估由当地诊所而不是研究团队开展的糖尿病干预措施的长期结果。